Chemed Revenue Growth Rates (CHE), Current and Historic Growth - CSIMarket
CSIMarket
 


Chemed Corporation  (NYSE: CHE)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

CHE's Revenue Growth by Quarter and Year

Chemed's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CHE/growth
https://api.csimarket.com/api/v1/companies/CHE/fundamentals
https://api.csimarket.com/api/v1/companies/CHE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
CHE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 690.94
2nd Quarter June 673.25
1st Quarter March 657.51
FY 2,021.70

CHEs Annual Revenue
Chemed's Revenue in the fiscal year 2025 $ 2,529.98 millions
Chemed's Revenue in the fiscal year 2024 $ 2,431.29 millions
Chemed's Revenue in the fiscal year 2023 $ 2,264.42 millions
Chemed's Revenue in the fiscal year 2022 $ 2,134.96 millions
Chemed's Revenue in the fiscal year 2021 $ 2,139.26 millions




CHE Revenue third quarter 2026 Y/Y Growth Comment
Chemed Corporation achieved in the third quarter 2026, above Company average Revenue increase of 10.57% year on year, to $ 690.94 millions.

Looking into third quarter 2026 results within Healthcare Facilities industry 12 other companies have achieved higher Revenue growth. While Chemed Corporation' s Revenue growth of 10.57% ranks overall at the positon no. 1886 in the third quarter 2026.




CHE Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.57 %
2nd Quarter June 8.8 %
1st Quarter March 1.63 %
FY   -

Financial Statements
Chemed's third quarter 2026 Revenue $ 690.94 millions CHE's Income Statement
Chemed's third quarter 2025 Revenue $ 624.90 millions Quarterly CHE's Income Statement


CHE Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.63 %
2nd Quarter June 2.39 %
1st Quarter March 2.84 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #13
Healthcare Sector #288
Overall #1886

Revenue Y/Y Growth Statistics
High Average Low
14.17 % 4.81 % -5.42 %
(Sep 30 2020)   (Mar 31 2014)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #13
Healthcare Sector #288
Overall #1886
Revenue Y/Y Growth Statistics
High Average Low
14.17 % 4.81 % -5.42 %
(Sep 30 2020)   (Mar 31 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Chemed's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
8.68 % 1.22 % -4.57 %
(Dec 31 2019)  


CHE's III. Quarter Q/Q Revenue Comment
Chemed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue growth of 2.63%, to $ 690.94 millions, from $673.25 millions in the second quarter.
CHE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Chemed's Revenue growth quarter on quarter, overall rank is 1445.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #15
Healthcare Sector #199
Overall #1445
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #15
Healthcare Sector #199
Overall #1445
Revenue Q/Q Growth Statistics
High Average Low
8.68 % 1.22 % -4.57 %
(Dec 31 2019)  


CHE's III. Quarter Q/Q Revenue Comment
Chemed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue growth of 2.63%, to $ 690.94 millions, from $673.25 millions in the second quarter.
CHE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Chemed's Revenue growth quarter on quarter, overall rank is 1445.


Chemed's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 2,661.04
Y / Y Revenue Growth (TTM) 5.15 %
Year on Year Revenue Growth Overall Ranking # 1768
Seqeuential Revenue Change (TTM) 2.54 %
Seq. Revenue Growth (TTM) Overall Ranking # 2554


Cumulative Revenue growth Comment
Chemed saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.15% year on year, to $ 2,661 millions if the fiscal year would have ended in Sep 30 2026.
Chemed's trailing twelve months Revenue growth was higher than company's average 4.77% and higher than 3.31% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.54 % from $2595 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at4.77%.

In the Healthcare sector 279 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 235 to 1768.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 27
Healthcare Sector # 280
Overall # 1768

Revenue TTM Y/Y Growth Statistics
High Average Low
10.4 %
4.77 %
-2.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 368
S&P 500 # 2554
Cumulative Revenue growth Comment
Chemed saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.15% year on year, to $ 2,661 millions if the fiscal year would have ended in Sep 30 2026.
Chemed's trailing twelve months Revenue growth was higher than company's average 4.77% and higher than 3.31% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.54 % from $2595 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at4.77%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 2.54 % increase from $2595 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 279 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 235 to 1768.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 27
Healthcare Sector # 280
Overall # 1768

Revenue TTM Y/Y Growth Statistics
High Average Low
10.4 %
4.77 %
-2.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 368
S&P 500 # 2554




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CHE's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Cv Sciences Inc 17.41%$ 17.410 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions


About Chemed Revenue Growth Rates (CHE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Chemed Corp (CIK 19584).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000019584-26-000024
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Chemed Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.